View Item 

Eudragit®-based microcapsules of probucol with a gut-bacterial processed secondary bile acid

Access Status
Fulltext not available
Authors
Mooranian, A.
Zamani, N.
Mikov, M.
Golocorbin-Kon, S.
Stojanovic, G.
Arfuso, Frank
Al-Salami, Hani
Date
2018
Type
Journal Article

Metadata
Show full item record
Citation
Mooranian, A. and Zamani, N. and Mikov, M. and Golocorbin-Kon, S. and Stojanovic, G. and Arfuso, F. and Al-Salami, H. 2018. Eudragit®-based microcapsules of probucol with a gut-bacterial processed secondary bile acid. Therapeutic Delivery. 9 (11): pp. 811-821.
Source Title
Therapeutic Delivery
DOI
ISSN
School
School of Pharmacy and Biomedical Sciences
URI
Collection
Abstract

© 2018 Newlands Press. Aim: Deoxycholic acid (DCA) has improved gliclazide oral absorption, while Eudragit® (ED) polymers have improved formulation stability of antidiabetic drugs. The aim of the study is to test if DCA and ED encapsulation will optimize the release and stability of the potential antidiabetic drug probucol (PB). Materials & methods: The PB formulations were prepared using ED polymers and DCA, and formulations were analyzed for their rheological and biological properties. Results: Rheological properties and size distribution were similar among all groups. ß-cell survival and biological activities were best with NM30D microcapsules. The inflammatory profile and oxidative stress effects of microcapsules remained similar among all groups. Conclusion: ED NM30D and DCA incorporation can exert positive and stabilizing effects on PB oral microcapsules.